In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot.
Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.
Utipro® Plus has been presented to HCP and available as capsules for oral administration in pharmacies all across the Israeli territory since Q4 2017.
Utipro® Plus is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Noventure SL)
Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” on Future Microbiology 2017; 12: 721-73, the authors presented a new communication at the VII International Congress of Histology and Tissue Engineering. Santiago de Compostela 5-8 Sept 2017.
The results confirm the non-pharmacological barrier effect of xyloglucan and its utility in the prevention of urinary tract infections.
